John Armbruster
Family · Bloomfield, MONPI 1003207242
Payments from drug & device makers
Across 234 payments — averaging $21.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- GSK$278
- Amgen$239
- AstraZeneca$200
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$191
- Otsuka America Pharmaceutical, Inc.$112
- plus $167 from 4 others
What the payments were for
- Food & beverage$5,086100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 185 | $3,900 |
| GSK | 18 | $278 |
| Amgen | 2 | $239 |
| AstraZeneca | 5 | $200 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $191 |
| Otsuka America Pharmaceutical, Inc. | 8 | $112 |
| Alkermes, Inc. | 5 | $105 |
| Boehringer Ingelheim | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,086 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 70 | $12,412 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $8,554 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,047 |
| JardianceEmpagliflozin | 30 | $5,982 |
| Rosuvastatin Calcium | 625 | $5,632 |
| XareltoRivaroxaban | 30 | $5,155 |
| VascepaIcosapent Ethyl | 31 | $3,923 |
| TradjentaLinagliptin | 27 | $3,571 |
| Valsartan | 234 | $3,401 |
| Gabapentin | 287 | $3,091 |
| Pantoprazole Sodium | 270 | $2,654 |
| Levocetirizine Dihydrochloride | 299 | $2,497 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,045 |
| Levothyroxine Sodium | 309 | $1,959 |
| Fluticasone Propionate | 68 | $1,856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $30 | $9,55357 claims |
| AstraZenecaBreztri Aerosphere | $200 | $8,55411 claims |
| GSKTrelegy Ellipta | $278 | $8,04712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Bloomfield
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.